Getting your player ready...
NEW YORK — Biotechnology company Genzyme Corp. said Monday it rejected Sanofi-Aventis SA’s $18.5 billion buyout offer because it undervalues the company.
Denver Post staff and wire reports
Genzyme rejects buyout bid
NEW YORK — Biotechnology company Genzyme Corp. said Monday it rejected Sanofi-Aventis SA’s $18.5 billion buyout offer because it undervalues the company.
Denver Post staff and wire reports
